# Defensive growth shines as rate fears ease — ride Eli Lilly's GLP-1 dominance

_AI-generated trading idea · LONG · LLY_

> Canonical page: https://commonquant.ai/research/for-you/defensive-growth-shines-as-rate-fears-ease-ride-eli-lilly-s--2884ef67-a51e-49f2-a593-52dd9cc00669

The broader stock market is breathing a sigh of relief as cooling job numbers ease fears of aggressive rate hikes. This favorable environment for stocks is the perfect backdrop for high-flying growth stories like Eli Lilly, which just secured massive Medicare coverage for its weight-loss drugs.

## Idea

Eli Lilly has a fundamental catalyst with Medicare inclusion for GLP-1 drugs, effectively guaranteeing a massive new revenue stream. The stock is hitting highs just as the weak jobs report takes the threat of rate hikes off the table. High-growth, defensive stocks like pharmaceutical companies thrive when rates are stable because their future earnings become more valuable. This creates a perfect environment to buy the momentum in LLY.

## Advanced Analysis

### Verdict: a real GLP-1 story, but the entry gate is far from open

This is a watch-list idea, not a trade. The strongest argument for it is real: Q2 2026 revenue rose 16.0% sequentially to $23.0B and operating cash flow surged 200% to $16.0B, funding the GLP-1 buildout and a dividend that has grown about 15.3% annually, while the Medicare GLP-1 catalyst per the July 1, 2026 Yahoo Finance piece remains backdrop. The strongest argument against is that the compiled entry never fired — zero entries across 1,237 daily bars — and no robust setup was established because the sensitivity evaluation exceeded its time budget, leaving the timing leg unproven. Meanwhile the stock sits about 5.7% below the $1,215.08 Donchian breakout line, trend strength is 11.1 versus the required 20, and the June 30, 2026 ownership filing (a delayed reporting period, not a current posture) shows about $2.9M net insider selling across 20 holders, with net margin slipping to 30.9% from 37.4% and debt-to-equity up to 1.41. A confirmed daily close above $1,215.08 with trend strength above 20 and a reclaim of the $1,185.78 EMA would flip this to actionable; a break toward the $1,110 support would deepen the case for standing aside.

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 65/100 |
| Trade readiness | 20/100 |
| Risk quality | 50/100 |
| Trigger proximity | 15/100 |
| Fundamentals trend | 60/100 |
| Score | 42/100 |
| Composite Score | 42/100 |
| Evidence Tier | rules\_not\_triggered |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | rules\_not\_triggered |

### Trade now: wait — the entry gate is still closed

This is a watch-list setup, not an active signal. The compiled entry requires a close above the 20-day Donchian upper band, a green candle, a break of the nearest resistance level, price above the 10-period EMA, and a trend-strength filter above 20 on the daily chart — with the trade routed through SPY as the market-environment proxy, so confirm you intend to express the LLY thesis through the ETF rather than LLY itself.

Live, none of the gate is close to firing. LLY last closed at $1,149.62 versus a Donchian band at $1,215.08 — roughly $65, or about 5.7%, below the breakout line. Price is also about $36 below the 10-day EMA at $1,185.78, so the trend filter is unmet, and trend strength sits at 11.1 versus the required 20 — the widest gap of all. Only the green-candle condition is currently met. RSI at 32.4 confirms a stock that has pulled back, not one breaking out.

If an entry triggered near the $1,215 Donchian level, the plan's exits are fixed: a stop about 2.3% below entry (roughly $1,187) and a take-profit about 4.5% above entry (roughly $1,270), an effective reward-to-risk near 2:1. That is only meaningful once the gate opens.

What 'wait' means concretely: do nothing today. Reassess only if LLY closes above $1,215.08 with the trend-strength filter above 20 and price reclaiming the 10-day EMA. No robust parameter setup was established — the sensitivity evaluation ran out of time budget — so do not loosen thresholds on your own to force a trade.

#### LLY price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | LLY |
| Timeframe | 1d |

### GLP-1 dominance plus a rate-friendly macro is a coherent bull setup

The idea's core claim — a fundamental catalyst in Medicare GLP-1 coverage layered on a macro tailwind from the weak June jobs report — is well matched to the fundamental picture. Per the Yahoo Finance piece on GLP-1 Medicare inclusion dated July 1, 2026, and the CNBC report of June 2, 2026 showing 57,000 jobs added versus expectations and a 4.2% unemployment rate, the macro backdrop (rates off the table for now) and the demand narrative arrived together. That aligns with the idea's thesis that stable-to-falling rates compress discount rates and favor high-growth pharma like Lilly. The numbers behind that demand story are real. Full-year 2025 revenue was $65.2B, up 44.7% year over year, with net income of…

#### LLY Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; +124.6% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \-0.3075084969648396% |
| 2009-06-30 | \0.13533878504672897% |
| 2009-09-30 | \0.3446138313982837% |
| 2009-09-30 | \0.09508329126703684% |
| 2009-12-31 | \0.45445287812457347% |
| 2010-03-31 | \0.1192949924968697% |
| 2010-06-30 | \0.13178900471896282% |
| 2010-09-30 | \0.10502599653379548% |
| 2010-12-31 | \0.4081624437412945% |
| 2011-03-31 | \0.07577758321252745% |
| Latest Value | \0.07577758321252745% |
| Change Pct | \124.642435562095% |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY Debt to equity

Debt to equity trend from CommonQuant fundamentals/XBRL data; -46.2% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \0.685055731184232 ratio |
| 2009-06-30 | \0.7813084112149533 ratio |
| 2009-09-30 | \0.6834628975265018 ratio |
| 2009-12-31 | \0.6965344923519469 ratio |
| 2010-03-31 | \0.6366955640729094 ratio |
| 2010-06-30 | \0.670444442273309 ratio |
| 2010-09-30 | \0.562814880496554 ratio |
| 2010-12-31 | \0.545115657431785 ratio |
| 2011-03-31 | \0.36833115643524567 ratio |
| Latest Value | \0.36833115643524567 ratio |
| Change Pct | \-46.233402675352494 ratio |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY sector percentile check

Ranks LLY against 986 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Return on equity | \90.46653144016229th percentile |
| Gross margin | \79.30283224400871th percentile |
| Revenue growth (YoY) | \58.67269984917044th percentile |
| Ticker | LLY |
| Sector | Health Care |
| Peer Count | 986 |

### Scores

- **Conviction score breakdown:** 42
- **Thesis support:** 65
- **Trade readiness:** 20
- **Risk quality:** 50
- **Trigger proximity:** 15
- **Fundamentals trend:** 60

### Watch items

- **LLY — Close vs Donchian (20) upper band**
- **LLY — Close vs EMA (10)**
- **SPY — ADX (14)**
- **LLY — Insider open-market net activity**
- **LLY — Next dividend ex-date**
- **LLY — Price vs support at $1,110.57**
- **LLY — Price above Donchian (20)**
- **LLY — Price below 1**
- **LLY — Price above Price**
- **LLY — Price above EMA (10)**
- **LLY — ADX (14) above 20**

## Key details

- Symbols: LLY
- Timeframes: D1
- Tags: \#stocks, \#healthcare, \#defensive\_growth

## Community

- Upvotes: 84
- Views: 1,466
- Copies: 0
- Cosigns: 0

## News sources

- [U.S. economy added 57,000 jobs in June, less than expected; unemployment rate at 4.2%](https://www.cnbc.com/2026/07/02/jobs-report-june-2026-.html) — CNBC
- [Stocks Climb as Fed Rate Hike Fears Ease on a Weak Jobs Report](https://finance.yahoo.com/markets/stocks/articles/stocks-climb-fed-rate-hike-140521912.html) — Yahoo Finance
- [Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results](https://finance.yahoo.com/healthcare/articles/eli-lilly-hits-highs-glp-142311427.html) — Yahoo Finance

## Discussion (1)

**@steady\_spread** · 1 upvotes

The LLY trend looks constructive, but chasing it on 1d could still be costly.

## Related

- [LLY trade ideas](https://commonquant.ai/markets/lly)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (over a timeframe-dependent historical window with walk-forward tuning) and stress-tested before they can go live, then monitored against the news hourly while they run.